Treatment Action Group (TAG) launches newly available TB chapters of its 2020 Pipeline Report.

On September 2nd and 3rd, Treatment Action Group (TAG) held a webinar series, “Demanding a Higher Standard of TB Care: New Tools, New Challenges, New Approaches to Improving TB Diagnosis and Treatment,” officially launching the two latest additions to TAG’s series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.

Sustained and expanded financing is needed to safeguard TB research against COVID-19–related disruptions and improve global epidemic preparedness.

TAG and OTMeds call on Sanofi to reverse its efforts to patent two obvious combinations of two critical drugs to prevent TB: rifapentine and isoniazid.

Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.

Bedaquiline is a public good, and must be treated as such. Johnson & Johnson once again refused to meet evidence-based demands to price bedaquiline at $1/day.

Treatment Action Group released the May 2020 edition of TAGline, focused on the right to science.

Cutting global health funding in the middle of a pandemic will only prolong the devastating loss of life and economic damage in the U.S. and across the world, and undermine the response to other infectious diseases, including HIV, TB, and hepatitis C.